Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.

@article{Kim2008ChangesIT,
  title={Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.},
  author={Jung Gu Kim and Jung Hwa Kim and Dong Ock Lee and Hoon Il Kim and Ja Yeon Kim and Chang Suk Suh and Seok Hyun Kim and Young Min Choi},
  journal={Menopause},
  year={2008},
  volume={15 2},
  pages={
          357-62
        }
}
  • Jung Gu Kim, Jung Hwa Kim, +5 authors Young Min Choi
  • Published in Menopause 2008
  • Medicine
  • OBJECTIVE To investigate changes in the serum levels of osteoprotegerin (OPG) and soluble receptor activator for nuclear factor kappaB ligand (sRANKL) after estrogen plus progestogen therapy (EPT) and to determine their relationships with changes in bone mineral density (BMD) and bone turnover markers in postmenopausal women. DESIGN Serum levels of OPG, sRANKL, and bone turnover markers, such as osteocalcin and type I C-telopeptide breakdown products, parathyroid hormone, calcitonin, calcium… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv